{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:11:10Z","timestamp":1787166670310,"version":"build-2736575974"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>The Neuromyelitis Optica Spectrum Disorders (NMOSD) constitute a spectrum of rare autoimmune diseases of the central nervous system characterized by episodes of transverse myelitis, optic neuritis, and other demyelinating attacks. Previously thought to be a subtype of multiple sclerosis, NMOSD is now known to be a distinct disease with unique pathophysiology, clinical course, and treatment options. Although there have been significant recent advances in the diagnosis and treatment of NMOSD, the field still lacks clinically validated biomarkers that can be used to stratify disease severity, monitor disease activity, and inform treatment decisions. Here we review many emerging NMOSD biomarkers including markers of cellular damage, neutrophil-to-lymphocyte ratio, complement, and cytokines, with a focus on how each biomarker can potentially be used for initial diagnosis, relapse surveillance, disability prediction, and treatment monitoring.<\/jats:p>","DOI":"10.3389\/fneur.2024.1415535","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:43:20Z","timestamp":1715820200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Soluble biomarkers for Neuromyelitis Optica Spectrum Disorders: a mini review"],"prefix":"10.3389","volume":"15","author":[{"given":"Rachel E.","family":"Rodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of Neuromyelitis Optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ana.26858","article-title":"Time to disability milestones and annualized relapse rates in NMOSD and MOGAD","volume":"95","author":"Duchow","year":"2023","journal-title":"Ann Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1212\/NXI.0000000000000947","article-title":"Discontinuation of immunosuppressive therapy in patients with Neuromyelitis Optica Spectrum disorder with Aquaporin-4 antibodies","volume":"8","author":"Kim","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2017.08.005","article-title":"Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: a multicenter cohort study","volume":"17","author":"Kessler","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1212\/NXI.0000000000000727","article-title":"Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD","volume":"7","author":"Jitprapaikulsan","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"116671","DOI":"10.1016\/j.jns.2020.116671","article-title":"Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD)","volume":"410","author":"Akaishi","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/cen3.12664","article-title":"Anti-aquaporin-4 positive-to-negative seroconversion in Latin American patients with neuromyelitis optica spectrum disorder treated with rituximab","volume":"12","author":"Zabala-\u00c1ngeles","year":"2021","journal-title":"Clin Exp Neuroim"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"865730","DOI":"10.3389\/fneur.2022.865730","article-title":"Glial fibrillary acidic protein in blood as a disease biomarker of Neuromyelitis Optica Spectrum disorders","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum Gfap and Neurofilament light as biomarkers of disease activity and disability in Nmosd","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","article-title":"Serum Neurofilament light and GFAP are associated with disease severity in inflammatory disorders with Aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Chang","year":"2021","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a Neuromyelitis Optica Spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-022-02450-w","article-title":"CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage","volume":"19","author":"Hyun","year":"2022","journal-title":"J Neuroinflammation"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e200188","DOI":"10.1212\/NXI.0000000000200188","article-title":"Serum biomarker profiles discriminate AQP4 seropositive and double seronegative Neuromyelitis Optica Spectrum disorder","volume":"11","author":"Carta","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/jnc.15478","article-title":"Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study","volume":"159","author":"Liu","year":"2021","journal-title":"J Neurochem"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e965","DOI":"10.1212\/NXI.0000000000000965","article-title":"Investigating the presence of Interattack astrocyte damage in Neuromyelitis Optica Spectrum disorder: longitudinal analysis of serum glial fibrillary acidic protein","volume":"8","author":"Hyun","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J Neuroinflammation"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/13524585211024978","article-title":"Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder","volume":"28","author":"Kim","year":"2022","journal-title":"Mult Scler"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"175628642110549","DOI":"10.1177\/17562864211054952","article-title":"Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder","volume":"14","author":"Zhang","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","article-title":"Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review","volume":"19","author":"Schindler","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"104100","DOI":"10.1016\/j.msard.2022.104100","article-title":"Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder","volume":"67","author":"Lin","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder","volume":"94","author":"Aktas","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5381239","article-title":"CSF-S100B is a potential candidate biomarker for Neuromyelitis Optica Spectrum disorders","volume":"2018","author":"Wei","year":"2018","journal-title":"Biomed Res Int"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neulet.2011.02.063","article-title":"Usefulness of serum S100B as a marker for the acute phase of aquaporin-4 autoimmune syndrome","volume":"494","author":"Fujii","year":"2011","journal-title":"Neurosci Lett"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1212\/01.wnl.0000256820.26489.17","article-title":"High CSF neurofilament heavy chain levels in neuromyelitis optica","volume":"68","author":"Miyazawa","year":"2007","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jocn.2020.11.016","article-title":"High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"83","author":"Liu","year":"2021","journal-title":"J Clin Neurosci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J Neurol Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e0281064","DOI":"10.1371\/journal.pone.0281064","article-title":"Clinical and imagenologic significance of the neutrophil-to-lymphocyte ratio in neuromyelitis optica spectrum disorder: a systematic review with meta-analysis","volume":"18","author":"Cabanillas-Lazo","year":"2023","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jocn.2022.05.002","article-title":"Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults","volume":"101","author":"Duan","year":"2022","journal-title":"J Clin Neurosci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000519835","article-title":"Distinct immunological features of inflammatory demyelinating diseases of the central nervous system","volume":"29","author":"Chen","year":"2022","journal-title":"Neuroimmunomodulation"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2147\/NDT.S311942","article-title":"Neutrophil-to-lymphocyte ratio on admission is an independent risk factor for the severity of neurological impairment at disease onset in patients with a first episode of Neuromyelitis Optica Spectrum disorder","volume":"17","author":"Zhou","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pediatrneurol.2023.03.009","article-title":"The neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio predict expanded disability status scale score at one year in pediatric Neuromyelitis Optica Spectrum disorder but not in multiple sclerosis","volume":"143","author":"Devlin","year":"2023","journal-title":"Pediatr Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12883-021-02432-0","article-title":"Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study","volume":"21","author":"Xie","year":"2021","journal-title":"BMC Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"628024","DOI":"10.3389\/fimmu.2021.628024","article-title":"An abnormally high neutrophil-to-lymphocyte ratio is not an independent outcome predictor in AQP4-IgG-positive NMOSD","volume":"12","author":"Carnero Contentti","year":"2021","journal-title":"Front Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica Spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msard.2019.06.035","article-title":"The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"35","author":"Qin","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"853891","DOI":"10.3389\/fimmu.2022.853891","article-title":"Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"577699","DOI":"10.1016\/j.jneuroim.2021.577699","article-title":"C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD","volume":"360","author":"Pache","year":"2021","journal-title":"J Neuroimmunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.molimm.2013.09.010","article-title":"A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission","volume":"57","author":"Veszeli","year":"2014","journal-title":"Mol Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s13760-023-02261-7","article-title":"C5a complement levels in clinical remission AQP4-IgG-positive NMO patients","volume":"123","author":"Manin","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult Scler"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jneuroim.2014.07.001","article-title":"Complement activation in patients with neuromyelitis optica","volume":"274","author":"Nytrova","year":"2014","journal-title":"J Neuroimmunol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jneuroim.2010.11.010","article-title":"Enhanced complement consumption in neuromyelitis optica and Beh\u00e7et\u2019s disease patients","volume":"233","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Neuroimmunol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1090548","DOI":"10.3389\/fimmu.2023.1090548","article-title":"Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders","volume":"14","author":"Miyamoto","year":"2023","journal-title":"Front Immunol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","article-title":"Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica","volume":"254","author":"Kuroda","year":"2013","journal-title":"J Neuroimmunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/sji.12132","article-title":"Increased soluble C5b-9 in CSF of neuromyelitis optica","volume":"79","author":"Wang","year":"2014","journal-title":"Scand J Immunol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1177\/1352458519887905","article-title":"Cerebrospinal fluid complement system biomarkers in demyelinating disease","volume":"26","author":"Zelek","year":"2020","journal-title":"Mult Scler"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e05899","DOI":"10.1016\/j.heliyon.2021.e05899","article-title":"CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder","volume":"7","author":"Namatame","year":"2021","journal-title":"Heliyon"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","article-title":"Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks","volume":"421","author":"Uzawa","year":"2013","journal-title":"Clin Chim Acta"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000494976","article-title":"Cytokines and tissue damage biomarkers in first-onset Neuromyelitis Optica Spectrum disorders: significance of Interleukin-6","volume":"25","author":"Wei","year":"2018","journal-title":"Neuroimmunomodulation"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000464135","article-title":"Cytokine and chemokine profiles in patients with Neuromyelitis Optica Spectrum disorder","volume":"23","author":"Wang","year":"2016","journal-title":"Neuroimmunomodulation"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e61835","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS One"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp.2011.241760","article-title":"CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse","volume":"83","author":"Uzawa","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"577925","DOI":"10.1016\/j.jneuroim.2022.577925","article-title":"IL-6 as a marker for NMOSD disease activity","volume":"370","author":"Haramati","year":"2022","journal-title":"J Neuroimmunol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2055217319848463","DOI":"10.1177\/2055217319848463","article-title":"Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases","volume":"5","author":"Hofer","year":"2019","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","volume":"183","author":"Barros","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10875-012-9709-9","article-title":"Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse","volume":"32","author":"Wang","year":"2012","journal-title":"J Clin Immunol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jneuroim.2011.10.001","article-title":"Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica","author":"Zhong","year":"2011","journal-title":"J Neuroimmunol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"677190","DOI":"10.3389\/fimmu.2021.677190","article-title":"Association of Circulating Follicular Helper T Cells and Serum CXCL13 with Neuromyelitis Optica Spectrum disorders","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/acn3.51094","article-title":"The CSF levels of neutrophil-related chemokines in patients with Neuromyelitis Optica","volume":"7","author":"Liu","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.14744\/nci.2022.77861","article-title":"Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"10","author":"Karaaslan","year":"2023","journal-title":"North Clin Istanb"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1027158","DOI":"10.3389\/fimmu.2022.1027158","article-title":"Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/acn3.51167","article-title":"Serum levels of cell adhesion molecules in patients with neuromyelitis optica spectrum disorder","volume":"7","author":"Chang","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"120385","DOI":"10.1016\/j.jns.2022.120385","article-title":"Clinical use of CSF neopterin levels in CNS demyelinating diseases","volume":"441","author":"Miyaue","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/ene.14128","article-title":"Urinalysis in patients with neuromyelitis optica spectrum disorder","volume":"27","author":"Chen","year":"2020","journal-title":"Eur J Neurol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"109875","DOI":"10.1016\/j.clim.2023.109875","article-title":"Renal dysfunction in AQP4 NMOSD and MS; a potential predictor of relapse and prognosis","volume":"259","author":"Chen","year":"2023","journal-title":"Clin Immunol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/acn3.51969","article-title":"Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis","volume":"11","author":"Abdelhak","year":"2024","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1415535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:43:24Z","timestamp":1715820204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1415535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":79,"alternative-id":["10.3389\/fneur.2024.1415535"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1415535","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"article-number":"1415535"}}